Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

August 31, 2011

Conditions
Glioblastoma Multiforme
Interventions
DRUG

MPC-6827 + Carboplatin

MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.

Trial Locations (5)

10029

Mt. Sinai School of Medicine, New York

30322

Emory University, Atlanta

77030

University of Texas MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute at the University of Utah, Salt Lake City

90025

The Angeles Clinic and Research Institute, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Myrexis Inc.

INDUSTRY

NCT00635557 - Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter